| Astrid Carolina Flores Burgos, OD | |
|
Lens Crafters- 2050 Ponce Bypass, Ponce, PR 00717 | |
| (787) 259-8882 | |
| Not Available |
| Full Name | Astrid Carolina Flores Burgos |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | Lens Crafters- 2050 Ponce Bypass, Ponce, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235902032 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 6335 (District Of Columbia) | Secondary |
| 152W00000X | Optometrist | 000768 (Puerto Rico) | Primary |
| Provider Name | Luxottica Of America Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1114223781 PECOS PAC ID: 2567366180 Enrollment ID: O20170605000893 |
News Archive
Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
A top executive for one of Britain's largest health and safety watchdogs is calling for a return to basic common sense following complaints that bureaucrats are attempting to eliminate all risk from all manner of pursuits in order to avoid costly lawsuits.
Research led by David H. Martin, MD, Professor and Chief of Infectious Diseases at LSU Health Sciences Center New Orleans, has found that a common sexually transmitted infection-causing parasite "cultivates" bacteria beneficial to it, changing thinking about which comes first-infection or bacteria.
Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Astrid Carolina Flores Burgos, OD Urb Las Alondras A45 Calle 3, Villalba, PR 00766 Ph: (787) 984-9344 | Astrid Carolina Flores Burgos, OD Lens Crafters- 2050 Ponce Bypass, Ponce, PR 00717 Ph: (787) 259-8882 |
News Archive
Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
A top executive for one of Britain's largest health and safety watchdogs is calling for a return to basic common sense following complaints that bureaucrats are attempting to eliminate all risk from all manner of pursuits in order to avoid costly lawsuits.
Research led by David H. Martin, MD, Professor and Chief of Infectious Diseases at LSU Health Sciences Center New Orleans, has found that a common sexually transmitted infection-causing parasite "cultivates" bacteria beneficial to it, changing thinking about which comes first-infection or bacteria.
Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.
› Verified 8 days ago
Glasses Optical Incorporado Optometrist Medicare: Medicare Enrolled Practice Location: 2939 Ave Emilio Fagot Ste 2, Ponce, PR 00716 Phone: 787-842-7033 | |
Dr. Jorge L. Bonilla Davila, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 2053 Ponce By Pass, Suite 104, Ponce, PR 00717 Phone: 787-848-2885 Fax: 787-848-4496 | |
Mrs. Rita Maria Pagan Silva, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 590 Calle Wito Morales, Urb Estancias Del Gulf, Ponce, PR 00730 Phone: 787-647-0227 | |
Insight Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: Plaza Caribe 2050 Ponce By Pass Ste 200, Ponce, PR 00717 Phone: 787-259-7059 | |
Dr. Jose A Perez, Optometrist Medicare: Not Enrolled in Medicare Practice Location: #108 Union, Ponce, PR 00731 Phone: 787-840-0993 Fax: 787-840-0993 | |
Ortiz Optometric Care Optometrist Medicare: Medicare Enrolled Practice Location: 8169 Calle Concordia, Condominio San Vicente Oficina 204, Ponce, PR 00731 Phone: 787-412-7822 |